Bayesian Capital Management LP Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Bayesian Capital Management LP acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 66,900 shares of the company's stock, valued at approximately $452,000.

Several other hedge funds also recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $233,000. Ameriprise Financial Inc. boosted its position in shares of Recursion Pharmaceuticals by 46.4% in the fourth quarter. Ameriprise Financial Inc. now owns 91,670 shares of the company's stock valued at $620,000 after acquiring an additional 29,034 shares during the period. Novo Holdings A S bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $368,000. Finally, Northern Trust Corp boosted its position in shares of Recursion Pharmaceuticals by 18.4% in the fourth quarter. Northern Trust Corp now owns 2,394,511 shares of the company's stock valued at $16,187,000 after acquiring an additional 371,886 shares during the period. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded up $0.17 during mid-day trading on Monday, hitting $4.50. 10,171,170 shares of the company were exchanged, compared to its average volume of 12,926,004. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $5.53 and a 200 day moving average of $6.67. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The company has a market capitalization of $1.81 billion, a PE ratio of -2.94 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The business's revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.